Saint John’s Cancer Institute
  • Home
  • About Us
    • Saint John’s Cancer Institute
      • Banchik Family Library
      • Blog
      • Events
      • In The News
      • Patents & Innovations
      • Research Administration
      • Translational Research Departments
    • Saint John’s Health Center
      • Cancer Support Services
      • Cancer Support Team
      • Contact a Specialist
      • COVID-19 Information
      • Visit the Health Center Website
    • Saint John’s Health Center Foundation
      • Inspiring Stories from Our Foundation
      • Make a Donation
      • Philanthropy Sponsored Programs
      • Webinars
      • Your Healthy Dose Podcast
      • Visit the Foundation Website
  • Centers of Excellence
    • Brain Tumors & Neuroscience
    • Breast Surgery and Oncology
    • Endocrine Tumors and Disorders
    • Gastrointestinal and Hepatobiliary Tumors
    • Gynecologic Oncology
    • Head and Neck Oncology
    • Melanoma, Skin and Soft Tissue Tumors
    • Pathology
    • Thoracic Surgical Oncology
    • Translational Research Departments
    • Urology and Urologic Oncology
  • Clinical Trials
    • Active Clinical Trials
    • Clinical Trials FAQs
    • COVID-19 Research
  • Fellowship Programs
    • Fellowship Overview
      • Recent Alumni & Current Fellows
    • Breast Surgical Oncology Fellowship
    • Donald L. Morton Complex General Surgical Oncology Fellowship
    • Neurosurgery Fellowship
    • Translational Molecular Medicine Fellowship
    • Urologic Oncology and Robotics Fellowship
  • Contact Us
    • Directory & Phone Numbers
    • Maps & Directions to Saint John’s Health Center
  • Access Providence My Chart
  • Search
  • Donate to Life-saving Research

Hematologic Cancer Clinical Trials

Clinical Trials Hematologic Cancer Clinical Trials

Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve subjects with follicular lymphoma.

Learn More

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve subjects with follicular lymphoma.

Learn More

I Want To:

Request an Appointment
Enter a Fellowship
Participate In A Clinical Trial
Donate Now
Careers

Connect With Us:

Locations Map
Contact Us
Main Facility Phone
310-315-6125
Providence Resource Line
888-432-5464

  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • YouTube

About Saint John’s Cancer Institute

Saint John’s Cancer Institute is a renowned research facility dedicated to advanced therapeutics, translational science, and best practices. We support fellowships and clinical trials, collaborating with industry and academic partners worldwide.

Administrative Office & Research Center:
2200 Santa Monica Blvd.
Santa Monica, CA 90404
Cancer Clinic:
Providence Saint John’s Health Center
2121 Santa Monica Blvd.
Santa Monica, CA 90404

©2023 Saint John’s Cancer Institute. All Rights Reserved. Site Map